Anti-Coagulants - Australia & Oceania

Australia & Oceania

In Australia & Oceania, the Anti-Coagulants market is anticipated to witness a significant increase in revenue, projected to reach US$355.60m in 2024.
This market is expected to maintain a steady annual growth rate (CAGR 2024-2029) of 7.66%, resulting in a market volume of US$514.30m by 2029.
When compared on a global scale, United States is predicted to generate the highest revenue in this market, with an estimated US$16,740.00m in 2024.
Australia's anti-coagulant market is witnessing a surge in demand due to an aging population and increasing prevalence of cardiovascular diseases.

Key regions: Australia, Japan, United States, Germany, Europe

Market

Region

Region comparison

Currency

Analyst Opinion

The Anti-Coagulants market in Australia & Oceania has been experiencing steady growth in recent years, driven by various factors such as an aging population, increased prevalence of cardiovascular diseases, and advancements in medical technology.

Customer preferences: Patients in Australia & Oceania have shown a preference for oral anti-coagulants over traditional injectable options. This is due to the convenience and ease of administration offered by oral medications. Additionally, patients are increasingly seeking personalized treatment options, with a focus on reducing the risk of adverse effects and improving overall quality of life.

Trends in the market: One trend that has been observed in the Australian anti-coagulants market is the growing popularity of direct oral anti-coagulants (DOACs). These medications have been shown to be as effective as traditional warfarin-based therapies, while also offering improved safety profiles and fewer drug interactions. As a result, DOACs are increasingly being prescribed as a first-line treatment option for patients with atrial fibrillation and other related conditions.Another trend in the Australian market is the increasing use of anti-coagulants for extended durations. This is due to the growing recognition of the benefits of long-term anti-coagulation therapy in reducing the risk of stroke and other cardiovascular events. As a result, patients are being prescribed anti-coagulants for longer periods of time, leading to increased demand for these medications.

Local special circumstances: Australia & Oceania has a unique healthcare system that places a strong emphasis on universal access to healthcare services. As a result, the demand for anti-coagulants in these regions is largely driven by the public healthcare system, which provides subsidized access to essential medications for all citizens. Additionally, the region has a large aging population, which is expected to drive continued growth in the anti-coagulants market in the coming years.

Underlying macroeconomic factors: The Australian economy has been growing steadily in recent years, driven by strong domestic demand and rising global commodity prices. This has led to increased investment in the healthcare sector, as well as greater government spending on healthcare services. Additionally, the region has a well-established pharmaceutical industry, with several major international players operating in the market. These factors are expected to support continued growth in the anti-coagulants market in Australia & Oceania in the coming years.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.